Nature Medicine Retracts Chronotherapy Trial After Integrity Review Flags Data Inconsistencies

The retracted study, originally published in 2025, randomized 312 patients across six Chinese centers and reported hazard ratios of 0.61 for morning versus afternoon infusions. Post-publication review identified mismatched electronic health record logs and missing source documents for dosing times, prompting the journal to state it no longer had confidence in result integrity. This case fits a documented pattern in which chronotherapy claims have repeatedly failed replication when independent timestamp audits are applied.

Prior observational work in The Lancet Oncology (2022) linked circadian timing to modest immune-response variation, yet those data were limited to surrogate cytokine markers without clinical endpoints. Regulatory filings with the NMPA show no requirement for time-stamped infusion logs in oncology trials, creating an evidentiary gap that allows protocol drift to remain undetected until retraction. The current episode therefore underscores how weak temporal data standards can propagate into practice guidelines.

Investigators have not released individual participant data for reanalysis, and the lead center has declined external audit. Future trials must incorporate continuous logging devices with real-time sponsor oversight; without such controls, timing-based dosing recommendations should remain investigational rather than adopted in routine care.